Mineralys Therapeutics (MLYS) Competitors $28.93 +13.45 (+86.90%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS vs. AKRO, ZLAB, MIRM, MLTX, PTGX, APLS, MENS, MTSR, SRRK, and KYMRShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Akero Therapeutics (AKRO), Zai Lab (ZLAB), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Jyong Biotech (MENS), Metsera (MTSR), Scholar Rock (SRRK), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Mineralys Therapeutics vs. Its Competitors Akero Therapeutics Zai Lab Mirum Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Apellis Pharmaceuticals Jyong Biotech Metsera Scholar Rock Kymera Therapeutics Mineralys Therapeutics (NASDAQ:MLYS) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk. Do insiders and institutionals believe in MLYS or AKRO? 84.5% of Mineralys Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, MLYS or AKRO? Mineralys Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.24, suggesting that its share price is 124% less volatile than the S&P 500. Which has higher earnings and valuation, MLYS or AKRO? Akero Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.56-8.13Akero TherapeuticsN/AN/A-$252.06M-$2.00-22.71 Does the media prefer MLYS or AKRO? In the previous week, Mineralys Therapeutics had 2 more articles in the media than Akero Therapeutics. MarketBeat recorded 12 mentions for Mineralys Therapeutics and 10 mentions for Akero Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.54 beat Akero Therapeutics' score of 1.45 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Akero Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MLYS or AKRO more profitable? Akero Therapeutics' return on equity of -15.84% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -70.44% -65.51% Akero Therapeutics N/A -15.84%-14.59% Do analysts recommend MLYS or AKRO? Mineralys Therapeutics presently has a consensus target price of $34.40, suggesting a potential upside of 18.90%. Akero Therapeutics has a consensus target price of $81.57, suggesting a potential upside of 79.61%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAkero Therapeutics beats Mineralys Therapeutics on 7 of the 13 factors compared between the two stocks. Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.94B$3.09B$5.68B$9.65BDividend YieldN/A2.28%6.66%4.53%P/E Ratio-8.2120.9382.6326.32Price / SalesN/A395.10533.52210.95Price / CashN/A43.5325.6628.92Price / Book7.539.9111.296.04Net Income-$177.81M-$54.01M$3.27B$265.75M7 Day Performance91.48%-0.24%0.04%-0.35%1 Month Performance111.80%9.02%8.20%5.55%1 Year Performance133.13%7.53%54.16%17.44% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics1.6336 of 5 stars$28.93+86.9%$34.40+18.9%+24.7%$1.94BN/A-8.2128News CoveragePositive NewsGap UpHigh Trading VolumeAKROAkero Therapeutics3.9816 of 5 stars$47.03-4.5%$81.57+73.4%+71.8%$3.94BN/A-23.5230News CoveragePositive NewsZLABZai Lab2.4056 of 5 stars$34.03-2.9%$56.35+65.6%+66.0%$3.92B$398.99M-16.681,869News CoverageMIRMMirum Pharmaceuticals3.4226 of 5 stars$71.81+0.4%$74.13+3.2%+71.4%$3.59B$429.16M-59.35140Positive NewsMLTXMoonLake Immunotherapeutics2.2744 of 5 stars$54.63-2.3%$74.43+36.2%+19.1%$3.59BN/A-19.652PTGXProtagonist Therapeutics1.5824 of 5 stars$56.88-1.0%$67.20+18.1%+37.7%$3.58B$434.43M81.26120News CoveragePositive NewsAPLSApellis Pharmaceuticals3.8524 of 5 stars$27.52-1.6%$34.12+24.0%-29.1%$3.53B$781.37M-15.12770News CoveragePositive NewsMENSJyong BiotechN/A$47.00+2.2%N/AN/A$3.50BN/A0.0031MTSRMetseraN/A$32.59-1.4%$55.00+68.8%N/A$3.47BN/A0.0081News CoverageAnalyst UpgradeSRRKScholar Rock4.4466 of 5 stars$33.33-6.1%$45.75+37.3%+251.1%$3.41B$33.19M-11.45140News CoveragePositive NewsKYMRKymera Therapeutics3.4172 of 5 stars$41.82-5.2%$58.76+40.5%-14.8%$3.15B$44.71M-12.05170Positive News Related Companies and Tools Related Companies AKRO Competitors ZLAB Competitors MIRM Competitors MLTX Competitors PTGX Competitors APLS Competitors MENS Competitors MTSR Competitors SRRK Competitors KYMR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLYS) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
